Arcturus Therapeutics to Present at the Following Investor Conferences in November
07 Novembro 2022 - 7:00PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,”
Nasdaq: ARCT), a global, late-stage clinical messenger RNA
medicines company focused on the development of infectious disease
vaccines and significant opportunities within liver and respiratory
rare diseases, today announced that the Company will present at the
following investor conferences.
Guggenheim 4th Annual Immunology and Neurology Day (Fireside
Chat)
- Tuesday, November 15, 2022 (2:45 p.m. ET)
34th Annual Piper Sandler Healthcare Conference
(Presentation)
- Tuesday, November 29, 2022 (11:30 a.m. ET)
If available, links can be found under the Investor
Relations/Events section of the Arcturus’ website.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes mRNA vaccine programs
for SARS-CoV-2 (COVID-19) and Influenza, and other programs to
potentially treat ornithine transcarbamylase (OTC) deficiency, and
cystic fibrosis, along with partnered programs including glycogen
storage disease type III, and hepatitis B virus. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, self-amplifying RNA, antisense RNA, circular RNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (patents and patent
applications issued in the U.S., Europe, Japan, China and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107006097/en/
IR and Media Contacts Arcturus Therapeutics
IR@arcturusrx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024